Daniel G. Welch is a businessperson who has been at the head of 8 different companies and holds the position of Non-Executive Chairman for Ultragenyx Pharmaceutical, Inc., Executive Chairman at InCarda Therapeutics, Inc. and Chairman at Nuvation Bio, Inc., Chairman of Nuvation Bio Operating Co., Inc. (a subsidiary of Nuvation Bio, Inc.). He is also on the board of Seagen Inc., Intercept Pharmaceuticals, Inc. and Levo Therapeutics, Inc. (former Executive Chairman). In the past Mr. Welch held the position of Executive Partner at Sofinnova Investments, Inc., Chairman & Chief Executive Officer at Triangle Pharmaceuticals, Inc., Chairman, President & Chief Executive Officer for InterMune, Inc., Chairman at AveXis, Inc., President-Biopharmaceuticals Division at Elan Corp. Plc, Principal at Adria Laboratories, Vice President-Worldwide Marketing at Sterling Winthrop, Inc. and Chief Operating Officer & Executive Vice President for Sanofi-Synthelabo, Inc. Daniel G. Welch received an undergraduate degree from the University of Miami and an MBA from The University of North Carolina at Charlotte.